La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the development of treatments that inhibits the activity of galectins as a means of treating human diseases, such as cancer and chronic organ failure. The Company was focused on the development and testing of Riquent as a treatment for Lupus nephritis. On January 19, 2012, the Company acquired rights to certain assets, including a clinical-stage compound designated GCS-100, from Solana Therapeutics, Inc. (Solana). The GCS-100 compound inhibits the expression of galectin-3. In March 2011, the Company, and Jewel Merger Sub, Inc., acquired the rights to compounds known as Regenerative Immunophilin Ligands (RILs) from GliaMed, Inc. (GliaMed). In June 2011, the Company sold the RILs back to GliaMed by selling interest of Jewel Merger Sub, Inc. to GliaMed.